Seminar Title: “Sequence-based design of small molecules targeting RNA structures”
Wednesday, October 6, from 3:30 – 5:00 via WebEx
https://uconn-cmr.webex.com/uconn-cmr/j.php?MTID=md6c4ed395e254712f67e8602b70efddf
Dr. Matthew Disney is a Professor in the Department of Chemistry, Florida Campus, Scripps Research
The Disney group develops rational approaches to design selective therapeutics from only genome sequence. One of the major advantages that genome sequencing efforts potentially provides is advancing patient-specific therapies, yet such developments have been only sparsely reported. We have developed general approach to provide lead Targeted Therapeutics and Precise Medicines that target RNAs that cause disease broadly and include rare neuromuscular (muscular dystrophy), neurodegenerative (Alzheimer’s, ALS), infectious diseases as well as difficult-to-treat cancers (breast, pancreatic, prostate, and others), and infectious diseases that can emerge through seasonal exposures. Designed compounds have demonstrated activity in human derived cellular disease models as well as pre-clinical animal models of disease. We train the next-generation of scientists to ensure our work has an exponential impact in studying disease biology and leveraging it into making Precision Medicines.
More information can be found here.
For more information, contact: Gregory Sartor at gregory.sartor@uconn.edu